authors
- McKenzie, MR
- Chi, KN
- Neville, Alan
- Ellard, S
- Baerg, B
- Ruether, D
- Winquist, E
- Segal, R
- Lukka, Himu
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- June 20, 2006
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal